Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Kirk © who wrote (1264)	5/19/2014 10:24:47 AM
From: Kirk ©	Respond to of 26783

Mergers and acquisition update AstraZeneca has rejected a "final" proposal of £55 a share, or £69B ($117B), from Pfizer ( PFE), saying that the bid "falls short of AstraZeneca's ( AZN) value as an independent science-led company." The U.K. company told Pfizer on Friday that any offer would have to be over 10% above the latter's previous bid of £53.50 a share. AstraZeneca said that Pfizer "has failed to make a compelling strategic, business or value case." AstraZeneca's shares were -11.1% premarket. AT&T has agreed to acquire DirecTV for $48.5B in a cash-and-stock deal worth $95 a share. The agreement would give AT&T ( T) 20.3M U.S. subscribers and 11.9M in Latin America, and access to the NFL's Sunday Ticket package. AT&T intends to sell its $6B, 8.4% holding in América Móvil ( AMX), a major rival to DirecTV ( DTV) in Latin America, in order to facilitate regulatory approval of the acquisition and avoid conflicts of interest.